Literature DB >> 33706759

Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19.

Hsin-Hsien Li1,2, Chen-Chi Liu1,3,4, Tien-Wei Hsu1,5, Jiun-Han Lin1,5, Jyuan-Wei Hsu3,4, Anna Fen-Yau Li4,6, Yi-Chen Yeh4,6, Shih-Chieh Hung7,8,9, Han-Shui Hsu10,11.   

Abstract

BACKGROUND: Air pollution exposure and idiopathic pulmonary fibrosis (IPF) cause a poor prognosis after SARS-CoV-2 infection, but the underlying mechanisms are not well explored. Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are the keys to the entry of SARS-CoV-2. We therefore hypothesized that air pollution exposure and IPF may increase the expression of ACE2 and TMPRSS2 in the lung alveolar region. We measured their expression levels in lung tissues of control non-IPF and IPF patients, and used murine animal models to study the deterioration of IPF caused by particulate matter (PM) and the molecular pathways involved in the expression of ACE2 and TMPRSS2.
RESULTS: In non-IPF patients, cells expressing ACE2 and TMPRSS2 were limited to human alveolar cells. ACE2 and TMPRSS2 were largely upregulated in IPF patients, and were co-expressed by fibroblast specific protein 1 (FSP-1) + lung fibroblasts in human pulmonary fibrotic tissue. In animal models, PM exposure increased the severity of bleomycin-induced pulmonary fibrosis. ACE2 and TMPRSS2 were also expressed in FSP-1+ lung fibroblasts in bleomycin-induced pulmonary fibrosis, and when combined with PM exposure, they were further upregulated. The severity of pulmonary fibrosis and the expression of ACE2 and TMPRSS2 caused by PM exposure were blocked by deletion of KC, a murine homologue of IL-8, or treatment with reparixin, an inhibitor of IL-8 receptors CXCR1/2.
CONCLUSIONS: These data suggested that risk of SARS-CoV-2 infection and COVID-19 disease severity increased by air pollution exposure and underlying IPF. It can be mediated through upregulating ACE2 and TMPRSS2 in pulmonary fibroblasts, and prevented by blocking the IL-8/CXCR1/2 pathway.

Entities:  

Keywords:  ACE2; Air pollution; COVID-19; Idiopathic pulmonary fibrosis; TMPRSS2

Mesh:

Substances:

Year:  2021        PMID: 33706759      PMCID: PMC7948665          DOI: 10.1186/s12989-021-00404-3

Source DB:  PubMed          Journal:  Part Fibre Toxicol        ISSN: 1743-8977            Impact factor:   9.400


  46 in total

1.  Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure.

Authors:  Kerri A Johannson; Eric Vittinghoff; Kiyoung Lee; John R Balmes; Wonjun Ji; Gilaad G Kaplan; Dong Soon Kim; Harold R Collard
Journal:  Eur Respir J       Date:  2013-10-31       Impact factor: 16.671

2.  Cytokine release syndrome in severe COVID-19.

Authors:  John B Moore; Carl H June
Journal:  Science       Date:  2020-04-17       Impact factor: 47.728

Review 3.  Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.

Authors:  Christopher S King; Steven D Nathan
Journal:  Lancet Respir Med       Date:  2016-09-03       Impact factor: 30.700

4.  Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.

Authors:  Ilona Glowacka; Stephanie Bertram; Marcel A Müller; Paul Allen; Elizabeth Soilleux; Susanne Pfefferle; Imke Steffen; Theodros Solomon Tsegaye; Yuxian He; Kerstin Gnirss; Daniela Niemeyer; Heike Schneider; Christian Drosten; Stefan Pöhlmann
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

5.  The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy.

Authors:  Sara Conti; Sergio Harari; Antonella Caminati; Antonella Zanobetti; Joel D Schwartz; Pietro A Bertazzi; Giancarlo Cesana; Fabiana Madotto
Journal:  Eur Respir J       Date:  2018-01-25       Impact factor: 16.671

6.  Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.

Authors:  Alessio Moriconi; Maria Candida Cesta; Maria Neve Cervellera; Andrea Aramini; Silvia Coniglio; Sandro Colagioia; Andrea Rosario Beccari; Cinzia Bizzarri; Michela Rita Cavicchia; Massimo Locati; Emanuela Galliera; Paola Di Benedetto; Paolo Vigilante; Riccardo Bertini; Marcello Allegretti
Journal:  J Med Chem       Date:  2007-08-01       Impact factor: 7.446

7.  ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19.

Authors:  Bruna G G Pinto; Antonio E R Oliveira; Youvika Singh; Leandro Jimenez; Andre N A Gonçalves; Rodrigo L T Ogava; Rachel Creighton; Jean Pierre Schatzmann Peron; Helder I Nakaya
Journal:  J Infect Dis       Date:  2020-07-23       Impact factor: 5.226

Review 8.  Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.

Authors:  Peter M George; Athol U Wells; R Gisli Jenkins
Journal:  Lancet Respir Med       Date:  2020-05-15       Impact factor: 30.700

9.  COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Authors:  Georg Schett; Michael Sticherling; Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2020-05       Impact factor: 53.106

10.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

Authors:  I Hamming; W Timens; M L C Bulthuis; A T Lely; G J Navis; H van Goor
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996

View more
  10 in total

1.  Effects of Air Pollution on Chemosensory Dysfunction in COVID-19 Patients.

Authors:  Young-Sook Choi; Byeong-Su Jeong; Yeon-Kyeng Lee; Yong-Dae Kim
Journal:  J Korean Med Sci       Date:  2022-10-10       Impact factor: 5.354

Review 2.  Regeneration-Associated Transitional State Cells in Pulmonary Fibrosis.

Authors:  Mengxia Shen; Ziqiang Luo; Yan Zhou
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

3.  On virus and nanomaterials - Lessons learned from the innate immune system - ACE activation in the invertebrate model Enchytraeus crypticus.

Authors:  M J B Amorim; S I L Gomes; R C S Bicho; J J Scott-Fordsmand
Journal:  J Hazard Mater       Date:  2022-05-18       Impact factor: 14.224

Review 4.  A review on the biological, epidemiological, and statistical relevance of COVID-19 paired with air pollution.

Authors:  Elizabeth F Yates; Kenneth Zhang; Abbie Naus; Callum Forbes; Xiao Wu; Tanujit Dey
Journal:  Environ Adv       Date:  2022-06-04

5.  The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland.

Authors:  Piotr Rzymski; Barbara Poniedziałek; Joanna Rosińska; Magdalena Rogalska; Dorota Zarębska-Michaluk; Marta Rorat; Anna Moniuszko-Malinowska; Beata Lorenc; Dorota Kozielewicz; Anna Piekarska; Katarzyna Sikorska; Anna Dworzańska; Beata Bolewska; Grzegorz Angielski; Justyna Kowalska; Regina Podlasin; Barbara Oczko-Grzesik; Włodzimierz Mazur; Aleksandra Szymczak; Robert Flisiak
Journal:  Environ Pollut       Date:  2022-05-14       Impact factor: 9.988

6.  Do COVID-19 containment measures work? Evidence from Switzerland.

Authors:  Regina Pleninger; Sina Streicher; Jan-Egbert Sturm
Journal:  Swiss J Econ Stat       Date:  2022-02-05

Review 7.  Involvement of the ACE2/Ang-(1-7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19.

Authors:  Taylor Morganstein; Zahraa Haidar; Joshua Trivlidis; Ilan Azuelos; Megan Jiaxin Huang; David H Eidelman; Carolyn J Baglole
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 8.  Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.

Authors:  Laure-Alix Clerbaux; Maria Cristina Albertini; Núria Amigó; Anna Beronius; Gillina F G Bezemer; Sandra Coecke; Evangelos P Daskalopoulos; Giusy Del Giudice; Dario Greco; Lucia Grenga; Alberto Mantovani; Amalia Muñoz; Elma Omeragic; Nikolaos Parissis; Mauro Petrillo; Laura A Saarimäki; Helena Soares; Kristie Sullivan; Brigitte Landesmann
Journal:  J Clin Med       Date:  2022-07-31       Impact factor: 4.964

Review 9.  Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis.

Authors:  Kota Kokubo; Atsushi Onodera; Masahiro Kiuchi; Kaori Tsuji; Kiyoshi Hirahara; Toshinori Nakayama
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

Review 10.  The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs.

Authors:  Hao Shen; Nu Zhang; Yuqing Liu; Xuerong Yang; Yuanyuan He; Qi Li; Xiaoyan Shen; Yulian Zhu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.